Search

Your search keyword '"Calles, Antonio"' showing total 310 results
Start Over Author "Calles, Antonio"
310 results on '"Calles, Antonio"'

1. RET Fusion Testing in Patients With NSCLC: The RETING Study

Author

Conde, Esther, Hernandez, Susana, Rodriguez Carrillo, Jose Luis, Martinez, Rebeca, Alonso, Marta, Curto, Daniel, Jimenez, Beatriz, Caminoa, Alejandra, Benito, Amparo, Garrido, Pilar, Clave, Sergi, Arriola, Edurne, Esteban-Rodriguez, Isabel, De Castro, Javier, Sansano, Irene, Felip, Enriqueta, Rojo, Federico, Dómine, Manuel, Abdulkader, Ihab, Garcia-Gonzalez, Jorge, Teixido, Cristina, Reguart, Noemi, Compañ, Desamparados, Insa, Amelia, Mancheño, Nuria, Palanca, Sarai, Juan-Vidal, Oscar, Baixeras, Nuria, Nadal, Ernest, Cebollero, Maria, Calles, Antonio, Martin, Paloma, Salas, Clara, Provencio, Mariano, Aranda, Ignacio, Massuti, Bartomeu, Lopez-Vilaro, Laura, Majem, Margarita, Paz-Ares, Luis, and Lopez-Rios, Fernando

Published
2024
Full Text
View/download PDF

2. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

Author

Aparicio, Inmaculada, Iranzo, Patricia, Reyes, Roxana, Bote, Helena, Saigi, María, Bringas, Marianela, Bosch-Barrera, Joaquim, Corral, Jesús, Aparisi, Francisco, Ruffinelli, Jose C., Jiménez, Beatriz, Lage, Yolanda, López-Castro, Rafael, Majem, Margarita, Vázquez, Sergio, Artal, Ángel, Rodríguez-Pérez, Ángel, Lázaro-Quintela, Martín, Torres, José Miguel Sánchez, Reguart, Noemí, Cucurull, Marc, Gil-Bazo, Ignacio, Camps, Carlos, Nadal, Ernest, del Barrio, Anabel, Garrido, Pilar, Dómine, Manuel, Álvarez, Rosa, Muñoz, Andrés J., and Calles, Antonio

Published
2023
Full Text
View/download PDF

3. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.

Author

Thavendiranathan, Paaladinesh, Zhang, Lili, Zafar, Amna, Drobni, Zsofia D, Mahmood, Syed S, Cabral, Marcella, Awadalla, Magid, Nohria, Anju, Zlotoff, Daniel A, Thuny, Franck, Heinzerling, Lucie M, Barac, Ana, Sullivan, Ryan J, Chen, Carol L, Gupta, Dipti, Kirchberger, Michael C, Hartmann, Sarah E, Weinsaft, Jonathan W, Gilman, Hannah K, Rizvi, Muhammad A, Kovacina, Bojan, Michel, Caroline, Sahni, Gagan, González-Mansilla, Ana, Calles, Antonio, Fernández-Avilés, Francisco, Mahmoudi, Michael, Reynolds, Kerry L, Ganatra, Sarju, Gavira, Juan José, González, Nahikari Salterain, García de Yébenes Castro, Manuel, Kwong, Raymond Y, Jerosch-Herold, Michael, Coelho-Filho, Otavio R, Afilalo, Jonathan, Zataraín-Nicolás, Eduardo, Baksi, A John, Wintersperger, Bernd J, Calvillo-Arguelles, Oscar, Ederhy, Stephane, Yang, Eric H, Lyon, Alexander R, Fradley, Michael G, and Neilan, Tomas G

Abstract

Myocarditis is a potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 mapping in ICI myocarditis are limited.This study sought to assess the value of CMR T1 and T2 mapping in patients with ICI myocarditis.In this retrospective study from an international registry of patients with ICI myocarditis, clinical and CMR findings (including T1 and T2 maps) were collected. Abnormal T1 and T2 were defined as 2 SD above site (vendor/field strength specific) reference values and a z-score was calculated for each patient. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block.Of 136 patients with ICI myocarditis with a CMR, 86 (63%) had T1 maps and 79 (58%) also had T2 maps. Among the 86 patients (66.3 ± 13.1 years of age), 36 (41.9%) had a left ventricular ejection fraction

Published
2021

4. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Author

Aldea, Mihaela, Marinello, Arianna, Duruisseaux, Michael, Zrafi, Wael, Conci, Nicole, Massa, Giacomo, Metro, Giulio, Monnet, Isabelle, Gomez Iranzo, Patricia, Tabbo, Fabrizio, Bria, Emilio, Guisier, Florian, Vasseur, Damien, Lindsay, Colin R., Ponce-Aix, Santiago, Cousin, Sophie, Citarella, Fabrizio, Fallet, Vincent, Minatta, Jose Nicolas, Eisert, Anna, de Saint Basile, Hortense, Audigier-Valette, Clarisse, Mezquita, Laura, Calles, Antonio, Mountzios, Giannis, Tagliamento, Marco, Remon Masip, Jordi, Raimbourg, Judith, Terrisse, Safae, Russo, Alessandro, Cortinovis, Diego, Rochigneux, Philippe, Pinato, David James, Cortellini, Alessio, Leonce, Camille, Gazzah, Anas, Ghigna, Maria-Rosa, Ferrara, Roberto, Dall’Olio, Filippo Gustavo, Passiglia, Francesco, Ludovini, Vienna, Barlesi, Fabrice, Felip, Enriqueta, Planchard, David, and Besse, Benjamin

Published
2023
Full Text
View/download PDF

5. Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis

Author

Quinaglia, Thiago, Gongora, Carlos, Awadalla, Magid, Hassan, Malek Z.O., Zafar, Amna, Drobni, Zsofia D., Mahmood, Syed S., Zhang, Lili, Coelho-Filho, Otavio R., Suero-Abreu, Giselle A., Rizvi, Muhammad A., Sahni, Gagan, Mandawat, Anant, Zatarain-Nicolás, Eduardo, Mahmoudi, Michael, Sullivan, Ryan, Ganatra, Sarju, Heinzerling, Lucie M., Thuny, Franck, Ederhy, Stephane, Gilman, Hannah K., Sama, Supraja, Nikolaidou, Sofia, Mansilla, Ana González, Calles, Antonio, Cabral, Marcella, Fernández-Avilés, Francisco, Gavira, Juan José, González, Nahikari Salterain, García de Yébenes Castro, Manuel, Barac, Ana, Afilalo, Jonathan, Zlotoff, Daniel A., Zubiri, Leyre, Reynolds, Kerry L., Devereux, Richard, Hung, Judy, Picard, Michael H., Yang, Eric H., Gupta, Dipti, Michel, Caroline, Lyon, Alexander R., Chen, Carol L., Nohria, Anju, Fradley, Michael G., Thavendiranathan, Paaladinesh, and Neilan, Tomas G.

Published
2022
Full Text
View/download PDF

6. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Author

Bar, Jair, Peled, Nir, Schokrpur, Shiruyeh, Wolner, Mirjana, Rotem, Ofer, Girard, Nicolas, Aboubakar Nana, Frank, Derijcke, Sofie, Kian, Waleed, Patel, Sandip, Gantz-Sorotsky, Hadas, Zer, Alona, Moskovitz, Mor, Metro, Giulio, Rottenberg, Yakir, Calles, Antonio, Hochmair, Maximilian, Cuppens, Kristof, Decoster, Lynn, Reck, Martin, Limon, Dror, Rodriguez, Estelamari, Astaras, Christoforos, Bettini, Adrienne, Häfliger, Simon, and Addeo, Alfredo

Published
2022
Full Text
View/download PDF

8. Lung cancer patients with COVID-19 in Spain: GRAVID study

Author

Provencio, Mariano, Mazarico Gallego, José María, Calles, Antonio, Antoñanzas, Mónica, Pangua, Cristina, Mielgo Rubio, Xabier, Nadal, Ernest, Castro, Rafael López, López-Martín, Ana, del Barco, Edel, Dómine, Manuel, Franco, Fernando, Diz, Pilar, Sandoval, Carmen, Girona, Elia Sais, Sullivan, Ivana, Sala, Mª Ángeles, Ledo, Gema García, Cucurull, Marc, Mosquera, Joaquín, Martínez, Mireia, Chara, Luis Enrique, Arriola, Edurne, Herrera, Beatriz Esteban, Jarabo, José Ramón, Álvarez, Rosa Álvarez, Baena, Javier, and Cao, María González

Published
2021
Full Text
View/download PDF

9. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy

Author

Mountzios, Giannis, de Toma, Alessandro, Economopoulou, Panagiota, Friedlaender, Alex, Banini, Marco, Lo Russo, Giuseppe, Baxevanos, Panagiotis, Roila, Fausto, Banna, Giuseppe Luigi, Christopoulou, Athina, Jimenez, Beatriz, Collazo-Lorduy, Ana, Linardou, Helena, Calles, Antonio, Galetta, Domenico, Addeo, Alfredo, Camerini, Andrea, Pizzutilo, Pamela, Kosmidis, Paris, Garassino, Marina Chiara, Proto, Claudia, Signorelli, Diego, and Metro, Giulio

Published
2021
Full Text
View/download PDF

10. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

Author

Ou,Sai-Hong, Le,Xiuning, Nagasaka,Misako, Reungwetwattana,Thanyanan, Ahn,Myung-Ju, Lim,Darren, Santos,Edgardo, Shum,Elaine, Lau,Sally, Lee,Jii Bum, Calles,Antonio, Wu,Fengying, Lopes,Gilberto, Sriuranpong,Virote, Tanizaki,Junko, Horinouchi,Hidehito, Garassino,Marina, Popat,Sanjay, Besse,Benjamin, Rosell,Rafael, Soo,Ross, Ou,Sai-Hong, Le,Xiuning, Nagasaka,Misako, Reungwetwattana,Thanyanan, Ahn,Myung-Ju, Lim,Darren, Santos,Edgardo, Shum,Elaine, Lau,Sally, Lee,Jii Bum, Calles,Antonio, Wu,Fengying, Lopes,Gilberto, Sriuranpong,Virote, Tanizaki,Junko, Horinouchi,Hidehito, Garassino,Marina, Popat,Sanjay, Besse,Benjamin, Rosell,Rafael, and Soo,Ross

Abstract

Sai-Hong Ignatius Ou,1 Xiuning Le,2 Misako Nagasaka,1 Thanyanan Reungwetwattana,3 Myung-Ju Ahn,4 Darren WT Lim,5 Edgardo S Santos,6 Elaine Shum,7 Sally CM Lau,7 Jii Bum Lee,8 Antonio Calles,9 Fengying Wu,10 Gilberto Lopes,11 Virote Sriuranpong,12 Junko Tanizaki,13 Hidehito Horinouchi,14 Marina C Garassino,15 Sanjay Popat,16 Benjamin Besse,17 Rafael Rosell,18 Ross A Soo19 1University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 4Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 5Duke-NUS School of medicine, National Cancer Center Singapore, Republic of Singapore; 6Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, 33431, USA; 7NYU Langone Perlmutter Cancer Center, NY, NY, USA; 8Yonsei Cancer Center Yonsei University, Seoul, Republic of Korea; 9Department of Medicine, Division of Medical Oncology, Early Drug Development and Phase I Unit, Hospital General Universitario Gregorio Marañón, Madrid, 28007, Spain; 10Shanghai Chest hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 11Department of Medicine, Division of Medical Oncology, Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, FL, 33136, USA; 12Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; 13Department of Medicine, Kindai University School of Medicine, Osaka, Japan; 14Department of Thoracic Oncology, National Cancer Center Hospital Tokyo, Tokyo, Japan; 15Department of Medicine, Division of Medical Oncology-Hematology, University of Chicago Medicine, Chicago, IL, USA; 16Royal Marsden Hospital, London, Imperial College, L

Published
2024

11. Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study

Author

Anguera, Georgia, Bosch, Joaquim, Cabezón, Luis, Catot, Silvia, Martinez, Alex, Muñoz, Silvia, Ramos, Inmaculada, Moran, Teresa, Taus, Alvaro, Arriola, Edurne, Aguado, Carlos, Dómine, Manuel, Rueda, Ana Gómez, Calles, Antonio, Cedrés, Susana, Viñolas, Nuria, Isla, Dolores, Palmero, Ramón, Sereno, María, Diaz, Victor, Juan, Oscar, Marsé, Raquel, Martorell, Paloma Martín, and Sánchez Torres, José Miguel

Published
2020
Full Text
View/download PDF

13. Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Author

Lee, Rebecca J., Wysocki, Oskar, Zhou, Cong, Shotton, Rohan, Tivey, Ann, Lever, Louise, Woodcock, Joshua, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina E., Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Frost, Hannah, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Huddar, Prerana, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, Mosenthal, Anne C., Obispo, Berta, Patel, Rushin, Pentheroudakis, George, Peters, Solange, Rieger-Christ, Kimberly, Robinson, Timothy, Rogado, Jacobo, Romano, Emanuela, Rowe, Michael, Sekacheva, Marina, Sheehan, Roseleen, Stevenson, Julie, Stockdale, Alexander, Thomas, Anne, Turtle, Lance, Viñal, David, Weaver, Jamie, Williams, Sophie, Wilson, Caroline, Palmieri, Carlo, Landers, Donal, Cooksley, Timothy, Dive, Caroline, Freitas, André, and Armstrong, Anne C.

Published
2022
Full Text
View/download PDF

18. Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

Author

Metro, Giulio, Banna, Giuseppe Luigi, Signorelli, Diego, Gili, Alessio, Galetta, Domenico, Galli, Giulia, Economopoulou, Panagiota, Roila, Fausto, Friedlaender, Alex, Camerini, Andrea, Christopoulou, Athina, Cantale, Ornella, De Toma, Alessandro, Pizzutilo, Pamela, Jimenez, Beatriz, Collazo-Lorduy, Ana, Calles, Antonio, Baxevanos, Panagiotis, Linardou, Helena, Kosmidis, Paris, Giannarelli, Diana, Mountzios, Giannis, and Addeo, Alfredo

Published
2020
Full Text
View/download PDF

19. Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A)

Author

Sanborn, Rachel E., primary, Waqar, Saiama N., additional, Cho, Byoung Chul, additional, Besse, Benjamin, additional, Goto, Koichi, additional, Wang, Yongsheng, additional, Lee, Se-Hoon, additional, Marmarelis, Melina E., additional, Ohe, Yuichiro, additional, Kim, Dong-Wan, additional, Calles, Antonio, additional, Neal, Joel, additional, Baik, Christina S., additional, Janne, Pasi A., additional, Curtin, Joshua C., additional, Patel, Bharvin, additional, Gormley, Mike, additional, Shreeve, S. Martin, additional, Bauml, Joshua M., additional, Knoblauch, Roland E., additional, and Yang, James Chih-Hsin, additional

Published
2023
Full Text
View/download PDF

20. Table S1 from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Author

Kosaka, Takayuki, primary, Tanizaki, Junko, primary, Paranal, Raymond M., primary, Endoh, Hideki, primary, Lydon, Christine, primary, Capelletti, Marzia, primary, Repellin, Claire E., primary, Choi, Jihyun, primary, Ogino, Atsuko, primary, Calles, Antonio, primary, Ercan, Dalia, primary, Redig, Amanda J., primary, Bahcall, Magda, primary, Oxnard, Geoffrey R., primary, Eck, Michael J., primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

21. Table S1, Table S2 from Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Author

Meulendijks, Didier, primary, Jacob, Wolfgang, primary, Voest, Emile E., primary, Mau-Sorensen, Morten, primary, Martinez-Garcia, Maria, primary, Taus, Alvaro, primary, Fleitas, Tania, primary, Cervantes, Andres, primary, Lolkema, Martijn P., primary, Langenberg, Marlies H.G., primary, De Jonge, Maja J., primary, Sleijfer, Stefan, primary, Han, Ji-Youn, primary, Calles, Antonio, primary, Felip, Enriqueta, primary, Kim, Sang-We, primary, Schellens, Jan H.M., primary, Wilson, Sabine, primary, Thomas, Marlene, primary, Ceppi, Maurizio, primary, Meneses-Lorente, Georgina, primary, James, Ian, primary, Vega-Harring, Suzana, primary, Dua, Rajiv, primary, Nguyen, Maitram, primary, Steiner, Lori, primary, Adessi, Celine, primary, Michielin, Francesca, primary, Bossenmaier, Birgit, primary, Weisser, Martin, primary, and Lassen, Ulrik N., primary

Published
2023
Full Text
View/download PDF

22. All supplemental Figures from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Author

Kosaka, Takayuki, primary, Tanizaki, Junko, primary, Paranal, Raymond M., primary, Endoh, Hideki, primary, Lydon, Christine, primary, Capelletti, Marzia, primary, Repellin, Claire E., primary, Choi, Jihyun, primary, Ogino, Atsuko, primary, Calles, Antonio, primary, Ercan, Dalia, primary, Redig, Amanda J., primary, Bahcall, Magda, primary, Oxnard, Geoffrey R., primary, Eck, Michael J., primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

24. Data from A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

Author

Atrafi, Florence, primary, Groen, Harry J.M., primary, Byers, Lauren A., primary, Garralda, Elena, primary, Lolkema, Martijn P., primary, Sangha, Randeep S., primary, Viteri, Santiago, primary, Chae, Young Kwang, primary, Camidge, D. Ross, primary, Gabrail, Nashat Y., primary, Hu, Beibei, primary, Tian, Tian, primary, Nuthalapati, Silpa, primary, Hoening, Elizabeth, primary, He, Lei, primary, Komarnitsky, Philip, primary, and Calles, Antonio, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figures from Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer

Author

Gibson, William J., primary, Ruan, Daniel T., primary, Paulson, Vera A., primary, Barletta, Justine A., primary, Hanna, Glenn J., primary, Kraft, Stefan, primary, Calles, Antonio, primary, Nehs, Matthew A., primary, Moore, Francis D., primary, Taylor-Weiner, Amaro, primary, Wala, Jeremiah A., primary, Zack, Travis I., primary, Lee, Thomas C., primary, Fennessy, Fiona M., primary, Alexander, Erik K., primary, Thomas, Tom, primary, Janne, Pasi A., primary, Garraway, Levi A., primary, Carter, Scott L., primary, Beroukhim, Rameen, primary, Lorch, Jochen H., primary, and Van Allen, Eliezer M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 2 from Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

Author

Garralda, Elena, primary, Paz, Keren, primary, López-Casas, Pedro P., primary, Jones, Siân, primary, Katz, Amanda, primary, Kann, Lisa M., primary, López-Rios, Fernando, primary, Sarno, Francesca, primary, Al-Shahrour, Fátima, primary, Vasquez, David, primary, Bruckheimer, Elizabeth, primary, Angiuoli, Samuel V., primary, Calles, Antonio, primary, Diaz, Luis A., primary, Velculescu, Victor E., primary, Valencia, Alfonso, primary, Sidransky, David, primary, and Hidalgo, Manuel, primary

Published
2023
Full Text
View/download PDF

27. Data from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Author

Kosaka, Takayuki, primary, Tanizaki, Junko, primary, Paranal, Raymond M., primary, Endoh, Hideki, primary, Lydon, Christine, primary, Capelletti, Marzia, primary, Repellin, Claire E., primary, Choi, Jihyun, primary, Ogino, Atsuko, primary, Calles, Antonio, primary, Ercan, Dalia, primary, Redig, Amanda J., primary, Bahcall, Magda, primary, Oxnard, Geoffrey R., primary, Eck, Michael J., primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 1 from Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

Author

Garralda, Elena, primary, Paz, Keren, primary, López-Casas, Pedro P., primary, Jones, Siân, primary, Katz, Amanda, primary, Kann, Lisa M., primary, López-Rios, Fernando, primary, Sarno, Francesca, primary, Al-Shahrour, Fátima, primary, Vasquez, David, primary, Bruckheimer, Elizabeth, primary, Angiuoli, Samuel V., primary, Calles, Antonio, primary, Diaz, Luis A., primary, Velculescu, Victor E., primary, Valencia, Alfonso, primary, Sidransky, David, primary, and Hidalgo, Manuel, primary

Published
2023
Full Text
View/download PDF

33. Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6 from Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Author

Meulendijks, Didier, primary, Jacob, Wolfgang, primary, Voest, Emile E., primary, Mau-Sorensen, Morten, primary, Martinez-Garcia, Maria, primary, Taus, Alvaro, primary, Fleitas, Tania, primary, Cervantes, Andres, primary, Lolkema, Martijn P., primary, Langenberg, Marlies H.G., primary, De Jonge, Maja J., primary, Sleijfer, Stefan, primary, Han, Ji-Youn, primary, Calles, Antonio, primary, Felip, Enriqueta, primary, Kim, Sang-We, primary, Schellens, Jan H.M., primary, Wilson, Sabine, primary, Thomas, Marlene, primary, Ceppi, Maurizio, primary, Meneses-Lorente, Georgina, primary, James, Ian, primary, Vega-Harring, Suzana, primary, Dua, Rajiv, primary, Nguyen, Maitram, primary, Steiner, Lori, primary, Adessi, Celine, primary, Michielin, Francesca, primary, Bossenmaier, Birgit, primary, Weisser, Martin, primary, and Lassen, Ulrik N., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Methods from Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

Author

Garralda, Elena, primary, Paz, Keren, primary, López-Casas, Pedro P., primary, Jones, Siân, primary, Katz, Amanda, primary, Kann, Lisa M., primary, López-Rios, Fernando, primary, Sarno, Francesca, primary, Al-Shahrour, Fátima, primary, Vasquez, David, primary, Bruckheimer, Elizabeth, primary, Angiuoli, Samuel V., primary, Calles, Antonio, primary, Diaz, Luis A., primary, Velculescu, Victor E., primary, Valencia, Alfonso, primary, Sidransky, David, primary, and Hidalgo, Manuel, primary

Published
2023
Full Text
View/download PDF

36. Supplemental Figure Legends from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Author

Kosaka, Takayuki, primary, Tanizaki, Junko, primary, Paranal, Raymond M., primary, Endoh, Hideki, primary, Lydon, Christine, primary, Capelletti, Marzia, primary, Repellin, Claire E., primary, Choi, Jihyun, primary, Ogino, Atsuko, primary, Calles, Antonio, primary, Ercan, Dalia, primary, Redig, Amanda J., primary, Bahcall, Magda, primary, Oxnard, Geoffrey R., primary, Eck, Michael J., primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

37. Supplemental Table S1 from Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2

Author

Tanizaki, Junko, primary, Ercan, Dalia, primary, Capelletti, Marzia, primary, Dodge, Michael, primary, Xu, Chunxiao, primary, Bahcall, Magda, primary, Tricker, Erin M., primary, Butaney, Mohit, primary, Calles, Antonio, primary, Sholl, Lynette M., primary, Hammerman, Peter S., primary, Oxnard, Geoffrey R., primary, Wong, Kwok-Kin, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

38. Supplemental Figure Legends from Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2

Author

Tanizaki, Junko, primary, Ercan, Dalia, primary, Capelletti, Marzia, primary, Dodge, Michael, primary, Xu, Chunxiao, primary, Bahcall, Magda, primary, Tricker, Erin M., primary, Butaney, Mohit, primary, Calles, Antonio, primary, Sholl, Lynette M., primary, Hammerman, Peter S., primary, Oxnard, Geoffrey R., primary, Wong, Kwok-Kin, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figures 1 - 3 from Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2

Author

Tanizaki, Junko, primary, Ercan, Dalia, primary, Capelletti, Marzia, primary, Dodge, Michael, primary, Xu, Chunxiao, primary, Bahcall, Magda, primary, Tricker, Erin M., primary, Butaney, Mohit, primary, Calles, Antonio, primary, Sholl, Lynette M., primary, Hammerman, Peter S., primary, Oxnard, Geoffrey R., primary, Wong, Kwok-Kin, primary, and Jänne, Pasi A., primary

Published
2023
Full Text
View/download PDF

40. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain

Author

Presa,María, Vicente,David, Calles,Antonio, Salinas-Ortega,Laura, Naik,Jaesh, García,Luis F, Soto,Javier, Presa,María, Vicente,David, Calles,Antonio, Salinas-Ortega,Laura, Naik,Jaesh, García,Luis F, and Soto,Javier

Abstract

María Presa,1 David Vicente,2 Antonio Calles,3 Laura Salinas-Ortega,1 Jaesh Naik,4 Luis F García,5 Javier Soto6 1Health Economics, Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain; 2Medical Oncology Department, Hospital Universitario Virgen de Macarena, Sevilla, Spain; 3Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain; 4Health Economics, BresMed Health Solutions, Sheffield, UK; 5Oncology Medical, Pfizer, Madrid, Spain; 6Health Economics & Outcomes Research, Pfizer, Madrid, SpainCorrespondence: María Presa, Pº Joaquín Rodrigo 4- letra I, Pozuelo de Alarcón, Madrid, 28224, Spain, Tel +34 917 157 147, Email mpresa@porib.comPurpose: The objective of the present study was to evaluate the efficiency of lorlatinib compared to alectinib and brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated, in Spain.Methods: A partitioned survival model comprised progression free, non-intracranial progression, intracranial progression, and death health states was constructed to estimate the total costs, life-years gained (LYG) and quality-adjusted life years (QALYs) accumulated in a lifetime horizon. Overall survival (OS) and progression-free survival (PFS) for lorlatinib were obtained from the CROWN study. For alectinib and brigatinib, a network meta-analysis of randomized controlled trials was conducted to estimate OS and PFS hazard ratios versus crizotinib. Utilities were estimated based on EQ-5D-5L data derived from the CROWN (lorlatinib), ALEX (alectinib) and ALTA-1L (brigatinib) studies. According to the Spanish National Health Service perspective the total costs (expressed in euros using a 2021 cost year) included drug acquisition and the administration’s subsequent treatment, ALK+ advanced NSCLC management and adverse-event management, and palliative care. Unitary costs were obtained from local cos

Published
2023

42. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

Author

Bar, Jair, primary, Peled, Nir, additional, Schokrpur, Shiruyeh, additional, Wolner, Mirjana, additional, Rotem, Ofer, additional, Girard, Nicolas, additional, Aboubakar Nana, Frank, additional, Derijcke, Sofie, additional, Kian, Waleed, additional, Patel, Sandip, additional, Gantz-Sorotsky, Hadas, additional, Zer, Alona, additional, Moskovitz, Mor, additional, Metro, Giulio, additional, Rottenberg, Yakir, additional, Calles, Antonio, additional, Hochmair, Maximilian, additional, Cuppens, Kristof, additional, Decoster, Lynn, additional, Reck, Martin, additional, Limon, Dror, additional, Rodriguez, Estelamari, additional, Astaras, Christoforos, additional, Bettini, Adrienne, additional, Häfliger, Simon, additional, and Addeo, Alfredo, additional

Published
2023
Full Text
View/download PDF

43. Aligning digital CD8+ scoring and targeted next‐generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early‐stage squamous cell lung carcinoma†

Author

Conde, Esther, Caminoa, Alejandra, Dominguez, Carolina, Calles, Antonio, Walter, Stefan, Angulo, Barbara, Sánchez, Elena, Alonso, Marta, Jimenez, Luis, Madrigal, Luis, Hernando, Florentino, Sanz‐Ortega, Julian, Jimenez, Beatriz, Garrido, Pilar, Paz‐Ares, Luis, de Castro, Javier, Hernandez, Susana, and Lopez‐Rios, Fernando

Published
2018
Full Text
View/download PDF

44. Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App

Author

Escudero-Vilaplana, Vicente, primary, Romero-Medrano, Lorena, additional, Villanueva-Bueno, Cristina, additional, Rodríguez de Diago, Marta, additional, Yánez-Montesdeoca, Alberto, additional, Collado-Borrell, Roberto, additional, Campaña-Montes, Juan José, additional, Marzal-Alfaro, Belén, additional, Revuelta-Herrero, José Luis, additional, Calles, Antonio, additional, Galera, Mar, additional, Álvarez, Rosa, additional, Herranz, Ana, additional, Sanjurjo, María, additional, and Artés-Rodríguez, Antonio, additional

Published
2022
Full Text
View/download PDF

45. Abstract 4019: RET-MAP: An international multi-center study of patients with advanced non-small cell lung cancer and RET fusions

Author

Aldea, Mihaela, primary, Marinello, Arianna, additional, Zrafi, Wael, additional, Tabbo, Fabrizio, additional, Guisier, Florian, additional, Vasseur, Damien, additional, Fallet, Vincent, additional, Audigier-Valette, Clarisse, additional, Mezquita, Laura, additional, Calles, Antonio, additional, Mountzios, Giannis, additional, Tagliamento, Marco, additional, Raimbourg, Judith, additional, Terrisse, Safae, additional, Novello, Silvia, additional, Ghigna, Maria-Rosa, additional, Barlesi, Fabrice, additional, Planchard, David, additional, and Besse, Benjamin, additional

Published
2022
Full Text
View/download PDF

46. A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.

Author

Calles, Antonio, primary, Navarro, Alejandro, additional, Doger, Bernard, additional, de Miguel, Maria J., additional, Alvarez Alvarez, Rosa Maria, additional, Moreno, Victor, additional, Ramón, Jorge, additional, Galera López, María del Mar, additional, Hernandez-Guerrero, Tatiana, additional, Corral, Elena, additional, and Calvo, Emiliano, additional

Published
2022
Full Text
View/download PDF

47. Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms.

Author

UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Bar, Jair, Peled, Nir, Schokrpur, Shiruyeh, Dudnik, Elizabeth, Wollner, Mira, Girard, Nicolas, Aboubakar Nana, Frank, Derijcke, Sofie, Kian, Waleed, Patel, Sandip P., Gantz Sorotsky, Hadas Yocheved, Zer, Alona, Moskovitz, Mor, Metro, Giulio, Rottenberg, Yakir, Calles, Antonio, Hochmair, Maximilian, Cuppens, Kristof, Decoster, Lynn, Addeo, Alfredo, UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, Bar, Jair, Peled, Nir, Schokrpur, Shiruyeh, Dudnik, Elizabeth, Wollner, Mira, Girard, Nicolas, Aboubakar Nana, Frank, Derijcke, Sofie, Kian, Waleed, Patel, Sandip P., Gantz Sorotsky, Hadas Yocheved, Zer, Alona, Moskovitz, Mor, Metro, Giulio, Rottenberg, Yakir, Calles, Antonio, Hochmair, Maximilian, Cuppens, Kristof, Decoster, Lynn, and Addeo, Alfredo

Abstract

BACKGROUND : About 10% of EGFR mutations (EGFRm) are ‘uncommon mutations’ (ucEGFRm). osimertinib is a 3rd generation EGFRi, active against common EGFRm. We aimed to collect real-world data about systemic and brain response and resistance mechanisms to osimertinib for ucEGFRm patients.

Published
2022

48. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).

Author

UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - (SLuc) Service de pneumologie, Bar, Jair, Peled, Nir, Schokrpur, Shiruyeh, Wolner, Mirjana, Rotem, Ofer, Girard, Nicolas, Aboubakar Nana, Frank, Derijcke, Sofie, Kian, Waleed, Patel, Sandip, Gantz-Sorotsky, Hadas, Zer, Alona, Moskovitz, Mor, Metro, Giulio, Rottenberg, Yakir, Calles, Antonio, Hochmair, Maximilian, Cuppens, Kristof, Decoster, Lynn, Reck, Martin, Limon, Dror, Rodriguez, Estelamari, Astaras, Christoforos, Bettini, Adrienne, Häfliger, Simon, Addeo, Alfredo, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - SSS/DDUV/GECE - Génétique cellulaire, UCL - (SLuc) Service de pneumologie, Bar, Jair, Peled, Nir, Schokrpur, Shiruyeh, Wolner, Mirjana, Rotem, Ofer, Girard, Nicolas, Aboubakar Nana, Frank, Derijcke, Sofie, Kian, Waleed, Patel, Sandip, Gantz-Sorotsky, Hadas, Zer, Alona, Moskovitz, Mor, Metro, Giulio, Rottenberg, Yakir, Calles, Antonio, Hochmair, Maximilian, Cuppens, Kristof, Decoster, Lynn, Reck, Martin, Limon, Dror, Rodriguez, Estelamari, Astaras, Christoforos, Bettini, Adrienne, Häfliger, Simon, and Addeo, Alfredo

Abstract

INTRODUCTION: Approximately 10% of EGFR mutations (EGFRmuts) are uncommon (ucEGFRmuts). We aimed to collect real-world data about osimertinib for patients with ucEGFRmuts. METHODS: This is a multicenter, retrospective study of ucEGFRmut (exon 20 insertions excluded) metastatic NSCLC treated with osimertinib as first EGFR inhibitor. The Response Evaluation Criteria in Solid Tumors and response assessment in neuro-oncology brain metastases brain objective response rate (ORR) were evaluated by the investigators. Median progression-free survival (mPFS), median overall survival, and median duration of response (mDOR) were calculated from osimertinib initiation. Mutations found at resistance were collected. RESULTS: A total of 60 patients were included (22 centers, nine countries), with median age of 64 years, 75% females, and 83% Caucasian. The largest subgroups were G719X (30%), L861Q (20%), and de novo Thr790Met (T790M) (15%). The ORR was 61%, mPFS 9.5 months, mDOR 17.4 months, and median overall survival 24.5 months. Regarding patients with no concurrent common mutations or T790M (group A, n = 44), ORR was 60%, mPFS 8.6 months, and mDOR 11 months. For G719X, ORR was 47%, mPFS 8.8 months, and mDOR 9.1 months. For L861Q, ORR was 80%, mPFS 16 months, and mDOR 16 months. For de novo T790M, ORR was 44%, mPFS 12.7 months, and mDOR 46.2 months. Compound EGFRmut including common mutations had better outcome compared with only ucEGFRmut. For 13 patients with a response assessment in neuro-oncology brain metastases-evaluable brain metastases, brain ORR was 46%. For 14 patients, rebiopsy results were analyzed: four patients with additional EGFR mutation (C797S, D585Y, E709K), three with new TP53 mutation, one with c-Met amplification, one with PIK3CA mutation, and one with neuroendocrine transformation. CONCLUSIONS: Osimertinib was found to have an activity in ucEGFRmut with a high rate of disease control systemically and intracranially. Several resistance mechanisms were identi

Published
2022

49. Norbornene as Key for a Possible Efficient Chemical Recycling in Structures Based on Ethylene

Author

Comunidad de Madrid, Agencia Estatal de Investigación (España), Calles, Antonio, García-Peñas, Alberto, Cerrada, María L., Gómez-Elvira González, José Manuel, Comunidad de Madrid, Agencia Estatal de Investigación (España), Calles, Antonio, García-Peñas, Alberto, Cerrada, María L., and Gómez-Elvira González, José Manuel

Abstract

Different circular strategies attempt to increase the energy efficiency or reduce the accumulation of plastic in landfills through the development of circular polymers. Chemical recycling is essential to recover the initial monomers from plastic residues for obtaining new goods showing the same properties as those using virgin monomers from the initial feedstocks. This work addresses the preparation of poly(ethylene-co-norbornene) copolymers for a promising generation of materials for energy applications that could be treated by chemical recycling. The thermal and thermo-oxidative stability for these copolymers with norbornene is higher than for the neat PE, while their degradation exhibits an activation energy lower than that observed in PE, pointing out that chemical recycling would require a lower energy consumption.

Published
2022

50. An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

Author

Wysocki, Oskar, Zhou, Cong, Rogado, Jacobo, Huddar, Prerana, Shotton, Rohan, Tivey, Ann, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina, Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Lewis, Alexandra, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, Mosenthal, Anne C., Wysocki, Oskar, Zhou, Cong, Rogado, Jacobo, Huddar, Prerana, Shotton, Rohan, Tivey, Ann, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina, Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Lewis, Alexandra, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, and Mosenthal, Anne C.

Abstract

Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely severity of COVID-19 in patients with active cancer who present to hospital. We assessed the differences in presentation and outcomes of patients with cancer and COVID-19, depending on the wave of the pandemic. We examined differences in features at presentation and outcomes in patients worldwide, depending on the waves of the pandemic: wave 1 D614G (n = 1430), wave 2 Alpha (n = 475), and wave 4 Omicron variant (n = 63, UK and Spain only). The performance of CORONET was evaluated on 258, 48, and 54 patients for each wave, respectively. We found that mortality rates were reduced in subsequent waves. The majority of patients were vaccinated in wave 4, and 94% were treated with steroids if they required oxygen. The stages of cancer and the median ages of patients significantly differed, but features associated with worse COVID-19 outcomes remained predictive and did not differ between waves. The CORONET tool performed well in all waves, with scores in an area under the curve (AUC) of >0.72. We concluded that patients with cancer who present to hospital with COVID-19 have similar features of severity, which remain discriminatory despite differences in variants and vaccination status. Survival improved following the first wave of the pandemic, which may be associated with vaccination and the increased steroid use in those patients requiring oxygen. The CORONET model demonstrated good performance, independent of the SARS-CoV-2 variants.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results